On May 29, 2024, Enlivex Therapeutics Ltd. completed a securities purchase agreement resulting in a direct offering of 2,060,000 ordinary shares and several warrants, raising approximately $4.5 million for corporate purposes. This event, which occurred as part of their financing strategy on May 27, 2024, indicates a significant capital raise for the company.